Phase 2-3 Study of Silymarin on Cisplatin Induced Nephrotoxicity
This study will look for possible protective effects silymarin on kidney injury in patients
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Urine concentration of NGAL
All subject receive silymarin at dose of 420mg or placebo in three dose for 65 consecutive day, urine NGAL concentration will be measured.
up to 9 weeks
Iran: Ethics Committee